Mark S. Schroeder Sells 5,339 Shares of Laboratory Co. of America Holdings (NYSE:LH) Stock

Laboratory Co. of America Holdings (NYSE:LH) COO Mark S. Schroeder sold 5,339 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $249.23, for a total value of $1,330,638.97. Following the sale, the chief operating officer now directly owns 4,960 shares of the company’s stock, valued at approximately $1,236,180.80. This trade represents a 51.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Laboratory Co. of America Trading Down 1.0 %

Shares of LH opened at $254.31 on Thursday. The stock has a 50-day moving average price of $242.77 and a 200 day moving average price of $233.34. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The company has a market capitalization of $21.29 billion, a P/E ratio of 28.83, a P/E/G ratio of 1.71 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Sell-side analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s payout ratio is currently 32.65%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LH. Bank of America boosted their price target on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Barclays decreased their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research report on Friday, February 7th. Jefferies Financial Group upped their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, UBS Group decreased their target price on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and a consensus price target of $268.38.

Institutional Trading of Laboratory Co. of America

Several institutional investors and hedge funds have recently bought and sold shares of LH. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Laboratory Co. of America during the 4th quarter worth approximately $25,929,000. Jefferies Financial Group Inc. boosted its position in Laboratory Co. of America by 156.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 25,513 shares of the medical research company’s stock valued at $5,851,000 after purchasing an additional 15,582 shares during the period. Heck Capital Advisors LLC acquired a new position in Laboratory Co. of America during the 4th quarter valued at approximately $44,000. Forum Financial Management LP boosted its holdings in shares of Laboratory Co. of America by 93.9% during the fourth quarter. Forum Financial Management LP now owns 2,461 shares of the medical research company’s stock valued at $564,000 after acquiring an additional 1,192 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Laboratory Co. of America during the fourth quarter worth about $481,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.